Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diabetes Treatment Clear all
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

NCT00744926
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 29, 2026, 10:23 PM EDT
Not yet recruiting Not applicable Interventional

RCT to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes

NCT07124208
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Biophoton Generators
Device
Lead sponsor
First Institute of All Medicines
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery

NCT04784637
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 29, 2026, 10:23 PM EDT
Active, not recruiting No phase listed Observational

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

NCT05754281
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
2nd Gen LabPatch Glucose Sensing System
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY3209590, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Concord, California • Fresno, California • Ventura, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 29, 2026, 10:23 PM EDT
Recruiting Not applicable Interventional

The Treatment of Painful Diabetic Neuropathy With Diet

NCT07509671
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Peripheral Neuropathy With Type 2 Diabetes, Vegan Diet
Interventions
Diet, Medical management
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
Recruiting No phase listed Observational

Kidney Precision Medicine Project

NCT04334707
View directory record Official record
Conditions
Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury, Acute Renal Insufficiency, Kidney Failure, Acute, Kidney Insufficiency, Acute, Renal Failure, Acute, Renal Insufficiency, Acute, Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency, Kidney Insufficiency, Chronic, Type 1 Diabetes (T1D)
Interventions
Kidney Biopsy, MRI, Retina Scan
Procedure · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • New Haven, Connecticut • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
Not yet recruiting Not applicable Interventional

Digital Behavioral Therapy to Reduce Diabetes and Liver Disease Risk

NCT07032311
View directory record Official record
Conditions
Type 2 Diabetes, Liver Disease
Interventions
Behavioral Treatment
Device
Lead sponsor
SIPPA Solutions INC
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance
Interventions
U-500 Insulin delivered by Omnipod (disposable insulin pump)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 29, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

NCT01549964
View directory record Official record
Conditions
Glycemic Control
Interventions
Fasiglifam (TAK-875), Sitagliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 29, 2026, 10:23 PM EDT
Completed No phase listed Observational

Diabetic Treatment Adherence

NCT01318564
View directory record Official record
Conditions
Endocrine System Diseases
Interventions
Metformin, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes

NCT03150199
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Positive Psychology + Motivational Interviewing, MI-based Health Education Intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Sep 29, 2026, 10:23 PM EDT
Terminated Not applicable Interventional

Connected Pens for Diabetes Study

NCT03830216
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Connected insulin pen and smartphone app, Inactive connected insulin pen without smartphone app
Device
Lead sponsor
Companion Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer

NCT04938869
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Type 2 Diabetes Mellitus
Interventions
Educational Intervention, Medical Device Usage and Evaluation, Survey Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 29, 2026, 10:23 PM EDT
Recruiting Phase 3 Interventional

Vitamin D and Type 2 Diabetes - Treat-To-Target

NCT07448974
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes (T2DM)
Interventions
Vitamin D (Cholecalciferol ), Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System

NCT01390259
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Open-Loop, Closed-Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Sep 29, 2026, 10:23 PM EDT
Withdrawn Phase 4 Interventional

Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

NCT04697485
View directory record Official record
Conditions
HF - Heart Failure, Diabetes Mellitus
Interventions
Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

NCT00474630
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Comparative Trial Between 3 Types of Insulin Infusion Protocols

NCT00582309
View directory record Official record
Conditions
Hyperglycemia
Interventions
Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago Heights, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 29, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Therapeutic Choice Questionnaire Study

NCT00139763
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Educational Materials
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 29, 2026, 10:23 PM EDT
Not listed Not applicable Interventional

Diabetes Complication Control in Community Clinics (D4C) Trial

NCT02835287
View directory record Official record
Conditions
Diabetes, Hypertension, Dyslipidemia, Cardiovascular Disease
Interventions
Protocol-based integrated care
Other
Lead sponsor
Tulane University
Other
Eligibility
50 Years and older
Enrollment
11,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 29, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 29, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

NCT06981234
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetazolamide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 29, 2026, 10:23 PM EDT